-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Bromocriptine Mesylate is a potent, selective D2-like dopamine receptor agonist with pKi of 8.05±0.2. Depending on the D2-like dopamine receptor of the target tissue that Bromocriptine Mesylate binds to, it can decrease metabolic processes leading to glucose intolerance and insulin resistance, inhibit the release of pituitary prolactin, and stimulate motor activity in Parkinson's disease. Bromocriptine Mesylate has been approved for treatment of type 2 diabetes, pituitary prolactinomas, acromegaly and Parkinson's disease.
1. Gardner B, Strange PG. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. British Journal of Pharmacology, 1998, 124(5): 978-984.
2. Ozery M, Wadhwa R. Bromocriptine. [Updated 2021 May 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.
3. Seo EJ, Sugimoto Y, Greten HJ, et al. Repurposing of Bromocriptine for Cancer Therapy. Frontiers in pharmacology, 2018, 9: 1030.
4. Harish Kumar VS, Vinutha MB, Pradeep AN, et al. Bromocriptine, a Dopamine (d2) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub-Therapeutic Doses to Ameliorate Hyperglycaemia. Journal of clinical and diagnostic research, 2013, 7(9): 1904-1907.
-
- Properties
-
Overview